Cargando…

Elimination of Cervical Cancer: Challenges Promoting the HPV Vaccine in China

OBJECTIVE: Cervical cancers present major threats to women’s health in China. Eliminating cervical cancer in China is a huge challenge, with application of the HPV vaccine, which is an important part. METHODS: There are currently four HPV vaccines available in China: E-coli bv-HPV (Wantai, China), b...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Lihui, Xie, Xing, Liu, Jihong, Qiao, Youlin, Zhao, Fanghui, Wu, Ting, Zhang, Jun, Ma, Ding, Kong, Beihua, Chen, Wen, Zhao, Chao, Zhao, Yun, Li, Jingran, Li, Mingzhu, Xia, Ningshao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer India 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236217/
https://www.ncbi.nlm.nih.gov/pubmed/34222614
http://dx.doi.org/10.1007/s40944-021-00536-6
_version_ 1783714493111468032
author Wei, Lihui
Xie, Xing
Liu, Jihong
Qiao, Youlin
Zhao, Fanghui
Wu, Ting
Zhang, Jun
Ma, Ding
Kong, Beihua
Chen, Wen
Zhao, Chao
Zhao, Yun
Li, Jingran
Li, Mingzhu
Xia, Ningshao
author_facet Wei, Lihui
Xie, Xing
Liu, Jihong
Qiao, Youlin
Zhao, Fanghui
Wu, Ting
Zhang, Jun
Ma, Ding
Kong, Beihua
Chen, Wen
Zhao, Chao
Zhao, Yun
Li, Jingran
Li, Mingzhu
Xia, Ningshao
author_sort Wei, Lihui
collection PubMed
description OBJECTIVE: Cervical cancers present major threats to women’s health in China. Eliminating cervical cancer in China is a huge challenge, with application of the HPV vaccine, which is an important part. METHODS: There are currently four HPV vaccines available in China: E-coli bv-HPV (Wantai, China), bv-HPV, qv-HPV (GSK, UK), and 9v-HPV (MSD, USA). To observe the immunogenicity, efficacy, and safety of these four vaccines in China, we formed the "Chinese Expert Consensus on the Clinical Application of HPV Vaccine." RESULTS: At 7 months after vaccination, all vaccinated subjects had the same immunogenic response to either HPV16 or HPV18, ranging from 96 to 100%, and antibody production in girls aged 9–14 years was 2–3 times higher than that in adult women. Efficacy of the four vaccines against CIN2 + ranged from 87.3%  to 100%, with prevention of HPV-associated infection reaching 96% ~ 97% at 12 months. Clinical trials showed bv-HPV and qv-HPV vaccine were also safe in women aged 18–45 years. Clinical trials of the 9v-HPV vaccine are underway. HPV vaccination is currently voluntary and self-paid in China. The "Chinese Expert Consensus on the Clinical Application of HPV Vaccine" will work to promote the application of HPV vaccine in China. CONCLUSIONS: In clinical studies, the available HPV vaccines showed excellent efficacy, safety, and immunogenicity in Chinese women. We will continue strengthening screening and encouraging HPV vaccination.
format Online
Article
Text
id pubmed-8236217
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer India
record_format MEDLINE/PubMed
spelling pubmed-82362172021-06-28 Elimination of Cervical Cancer: Challenges Promoting the HPV Vaccine in China Wei, Lihui Xie, Xing Liu, Jihong Qiao, Youlin Zhao, Fanghui Wu, Ting Zhang, Jun Ma, Ding Kong, Beihua Chen, Wen Zhao, Chao Zhao, Yun Li, Jingran Li, Mingzhu Xia, Ningshao Indian J Gynecol Oncol Review Article OBJECTIVE: Cervical cancers present major threats to women’s health in China. Eliminating cervical cancer in China is a huge challenge, with application of the HPV vaccine, which is an important part. METHODS: There are currently four HPV vaccines available in China: E-coli bv-HPV (Wantai, China), bv-HPV, qv-HPV (GSK, UK), and 9v-HPV (MSD, USA). To observe the immunogenicity, efficacy, and safety of these four vaccines in China, we formed the "Chinese Expert Consensus on the Clinical Application of HPV Vaccine." RESULTS: At 7 months after vaccination, all vaccinated subjects had the same immunogenic response to either HPV16 or HPV18, ranging from 96 to 100%, and antibody production in girls aged 9–14 years was 2–3 times higher than that in adult women. Efficacy of the four vaccines against CIN2 + ranged from 87.3%  to 100%, with prevention of HPV-associated infection reaching 96% ~ 97% at 12 months. Clinical trials showed bv-HPV and qv-HPV vaccine were also safe in women aged 18–45 years. Clinical trials of the 9v-HPV vaccine are underway. HPV vaccination is currently voluntary and self-paid in China. The "Chinese Expert Consensus on the Clinical Application of HPV Vaccine" will work to promote the application of HPV vaccine in China. CONCLUSIONS: In clinical studies, the available HPV vaccines showed excellent efficacy, safety, and immunogenicity in Chinese women. We will continue strengthening screening and encouraging HPV vaccination. Springer India 2021-06-27 2021 /pmc/articles/PMC8236217/ /pubmed/34222614 http://dx.doi.org/10.1007/s40944-021-00536-6 Text en © Association of Gynecologic Oncologists of India 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Review Article
Wei, Lihui
Xie, Xing
Liu, Jihong
Qiao, Youlin
Zhao, Fanghui
Wu, Ting
Zhang, Jun
Ma, Ding
Kong, Beihua
Chen, Wen
Zhao, Chao
Zhao, Yun
Li, Jingran
Li, Mingzhu
Xia, Ningshao
Elimination of Cervical Cancer: Challenges Promoting the HPV Vaccine in China
title Elimination of Cervical Cancer: Challenges Promoting the HPV Vaccine in China
title_full Elimination of Cervical Cancer: Challenges Promoting the HPV Vaccine in China
title_fullStr Elimination of Cervical Cancer: Challenges Promoting the HPV Vaccine in China
title_full_unstemmed Elimination of Cervical Cancer: Challenges Promoting the HPV Vaccine in China
title_short Elimination of Cervical Cancer: Challenges Promoting the HPV Vaccine in China
title_sort elimination of cervical cancer: challenges promoting the hpv vaccine in china
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236217/
https://www.ncbi.nlm.nih.gov/pubmed/34222614
http://dx.doi.org/10.1007/s40944-021-00536-6
work_keys_str_mv AT weilihui eliminationofcervicalcancerchallengespromotingthehpvvaccineinchina
AT xiexing eliminationofcervicalcancerchallengespromotingthehpvvaccineinchina
AT liujihong eliminationofcervicalcancerchallengespromotingthehpvvaccineinchina
AT qiaoyoulin eliminationofcervicalcancerchallengespromotingthehpvvaccineinchina
AT zhaofanghui eliminationofcervicalcancerchallengespromotingthehpvvaccineinchina
AT wuting eliminationofcervicalcancerchallengespromotingthehpvvaccineinchina
AT zhangjun eliminationofcervicalcancerchallengespromotingthehpvvaccineinchina
AT mading eliminationofcervicalcancerchallengespromotingthehpvvaccineinchina
AT kongbeihua eliminationofcervicalcancerchallengespromotingthehpvvaccineinchina
AT chenwen eliminationofcervicalcancerchallengespromotingthehpvvaccineinchina
AT zhaochao eliminationofcervicalcancerchallengespromotingthehpvvaccineinchina
AT zhaoyun eliminationofcervicalcancerchallengespromotingthehpvvaccineinchina
AT lijingran eliminationofcervicalcancerchallengespromotingthehpvvaccineinchina
AT limingzhu eliminationofcervicalcancerchallengespromotingthehpvvaccineinchina
AT xianingshao eliminationofcervicalcancerchallengespromotingthehpvvaccineinchina